30th week of 2011 patent applcation highlights part 44 |
Patent application number | Title | Published |
20110183851 | PENOXSULAM AS A TURFGRASS, VINEYARD AND ORCHARD FLOOR HERBICIDE - Penoxsulam, 2-(2,2-difluoroethoxy)-N-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide, is useful in controlling broadleaf weeds and sedges in orchard floors. | 2011-07-28 |
20110183852 | BLOCK POLYMERS, COMPOSITIONS AND METHODS FOR USE FOR FOAMS, LAUNDRY DETERGENTS, AND SHOWER RINSES AND COAGULANTS - The present invention relates to a block polymeric material. Typically the block polymer comprises units capable of having an average cationic charge density of about 15 or less, preferably 5 or less, more preferably from about 0.05 to about 5, even more preferably from about 0.05 to about 2.77, even more preferably from about 0.1 to about 2.75, most preferably from about 0.75 to about 2.25 units per 100 daltons molecular weight at a pH of from about 4 to about 12. The polymeric material is a suds enhancer and a suds volume extender for personal care products such as soaps and shampoos. The compositions have increased effectiveness for preventing re-deposition of grease during hand and body washing. The polymers are also effective as a soil release agent in fabric cleaning compositions. The polymeric material is also effective in oil well treating foam, fire-fighting foam, hard surface cleaning foam, shaving cream, post-foaming shaving gel, dephiliatories and as a coagulant/retention aid for titanium dioxide in paper making. | 2011-07-28 |
20110183853 | SYSTEMS AND DEVICES FOR ELECTRICAL FILTERS - Adaptations and improvements to tubular metal powder filters include employing non-circular cross sectional geometries, aligning the inner conductor off-axis, replacing the inner conductive wire with a conductive trace carried on a printed circuit board, combining multiple filters within a single common outer conductive housing, and employing meandering and other non-parallel signal paths. The various adaptations and improvements are designed to accommodate single-ended and differential signaling, as well as superconducting and non-superconducting applications. | 2011-07-28 |
20110183854 | Method of qualifying niobium and/or other super conducting materials for reliable fabrication of superconducting radio frequency (SCRF) cavities - A method of qualifying Niobium and/or other super conducting materials for the reliable fabrication of SCRF cavities , which will invariably deliver high accelerating fields including: identification of the best superconducting lower critical field (H | 2011-07-28 |
20110183855 | SOMATIC HYPERMUTATION SYSTEMS - The present application relates to somatic hypermutation (SHM) systems and synthetic genes. Synthetic genes can be designed using computer-based approaches to increase or decrease susceptibility of a polynucleotide to somatic hypermutation. Genes of interest are inserted into the vectors and subjected to activation-induced cytidine deaminase to induce somatic hypermutation. Proteins or portions thereof encoded by the modified genes can be introduced into a SHM system for somatic hypermutation and proteins or portions thereof exhibiting a desired phenotype or function can be isolated for in vitro or in vivo diagnostic or therapeutic uses. | 2011-07-28 |
20110183856 | Diagnosis and Prognosis of Infectious Disease Clinical Phenotypes and other Physiologic States Using Host Gene Expression Biomarkers In Blood - The present invention provides a specific set of gene expression markers from peripheral blood leukocytes that are indicative of a host response to exposure, response, and recovery infectious pathogen infections. The present invention further provides methods for identifying the specific set of gene expression markers, methods of monitoring disease progression and treatment of infectious pathogen infections, methods of prognosing the onset of an infectious pathogen infection, and methods of diagnosing an infectious pathogen infection and identifying the pathogen involved. | 2011-07-28 |
20110183857 | NOVEL HUMAN SINGLE NUCLEOTIDE POLYMORPHISMS - Disclosed are methods for human identification utilizing newly discovered single nucleotide polymorphisms (SNPs) within CODIS loci which can cause allelic dropout. Also disclosed are kits useful in human identification. | 2011-07-28 |
20110183858 | GRADING OF BREAST CANCER - Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer. | 2011-07-28 |
20110183859 | INFLAMMATORY GENES AND MICRORNA-21 AS BIOMARKERS FOR COLON CANCER PROGNOSIS - Disclosed herein are methods for detecting a more aggressive form of a colon adenocarcinoma in a subject, thereby predicting the prognosis of the subject. The methods generally include determining an inflammatory gene expression signature in the colon adenocarcinoma and/or the adjacent non-cancerous tissue. In some embodiments, the inflammatory genes include, but are not limited to, PRG1, ANXA1, IL-17a, IL-23a FOXP3, HLA-DRA, IL-10, CD68 and IL-12a. In some embodiments, the method further includes detecting expression of microRNA-21 (miR-21) in the colon adenocarcinoma. Altered expression of one or more of the inflammatory genes or miR-21 indicates the prognosis of the subject. Also provided are arrays consisting essentially of probes specific for PRG1, ANXA1, IL-17 | 2011-07-28 |
20110183860 | Protein Aggregation Domains and Methods of Use Thereof - Using the Sup35 prion proteins of two distantly related yeast species, it is established that prion replication is initiated by small elements of primary sequence, which can be identified using arrays of short peptides. Subtle differences in replication elements govern the formation of distinct aggregate conformations (prion strains) and also determine their species-specific seeding activities. A Sup35 chimera that promiscuously forms prions in more than one species does so by virtue of carrying the replication element of each species. Mutations or conditions that cause the chimera to assemble into distinct prion strains favor recognition of distinct replication elements. Therefore, subtle differences in small sequences that constitute prion replication elements encode important determinants of prion propagation and transmission. The protein aggregation domains, methods for identification thereof, and polypeptides and higher order aggregates including the protein interaction domains, as well as arrays including peptides derived from an aggregation-prone polypeptide are provided. | 2011-07-28 |
20110183861 | METHODS TO STABILIZE PROTEINS AND POLYPEPTIDES - Methods of modifying and in particular stabilizing proteins and polypeptides by which a predetermined amino acid is introduced into selected positions of said protein or polypeptide to produce a small group of mutants. The methods are based on the premise that certain amino acids play a crucial role in the stability of proteins or polypeptides. Generated mutants can then be further analysed for stability and/or function, e.g. affinity. Furthermore, appropriate mutants may be combined to result in further optimized proteins or polypeptides. In addition, stabilized example polypeptides and suitable methods to identify and/or analyse de-stabilized or stabilized proteins or polypeptides are provided. The methods can be used to study the role of specific amino acids in protein structure and function and to develop new or improved, e.g. stabilized proteins and polypeptides such as antibodies and single variable domains. | 2011-07-28 |
20110183862 | MOLECULAR SIGNATURE OF LIVER TUMOR GRADE AND USE TO EVALUATE PROGNOSIS AND THERAPEUTIC REGIMEN - The present invention concerns a method to determine the gene expression profile on a sample previously obtained from a patient diagnosed for a liver tumor, comprising assaying the expression of a set of genes in this sample and determining the gene expression profile (signature). In a particular embodiment, said method enables to determine the grade of the liver tumor, such as hepatoblastoma (HB) or a hepatocellular carcinoma (HCC). The invention is also directed to kits comprising a plurality of pairs of primers or a plurality of probes specific for a set of genes, as well as to solid support or composition comprising a set of probes specific for a set of genes. These methods are useful to determine the grade of a liver tumor in a sample obtained from a patient, to determine the risk of developing metastasis and/or to define the therapeutic regimen to apply to a patient. | 2011-07-28 |
20110183863 | PROTEIN SCREENING METHODS - The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro. | 2011-07-28 |
20110183864 | METHOD FOR LUNG CANCER EARLY DETECTION AND PROGNOSIS - The present invention provides method for the prognosis or detection of lung cancer, notably for early detection of lung cancer, as well as a kit and a (micro) array suitable for said method. | 2011-07-28 |
20110183865 | Lipoxygenase - The inventors have found a novel fungal lipoxygenase from | 2011-07-28 |
20110183866 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer. | 2011-07-28 |
20110183867 | Polymer arrays for biofilm adhesion testing - This invention relates to a method of screening arrays of polymers having pre-determined surface energies. The polymer arrays of the present invention can be used to screen for microorganism adherence. More specifically the arrays can be used to screen for adherence of particular bacteria or fungi to particular polymers in the array. Furthermore, this invention relates to a method combining in-situ polymer synthesis with physico-chemical characterisation of the resulting polymer array and subsequent biological assays of bacterial or fungal adherence. This allows for high throughput screening and characterisation of candidate polymers which are not susceptible to bacterial or fungal adherence or which can be used to support bacterial or fungal adherence where such is required. The arrays can also be used to screen for inhibition or promotion of biofilm formation. | 2011-07-28 |
20110183868 | SOLUTION MICROARRAYS AND USES THEREOF - The present invention relates to solution microarrays. In particular, the present invention relates to an aqueous 2-phase system for solution microarrays and uses thereof. Additional embodiments are described herein. | 2011-07-28 |
20110183869 | OXIDE LAYERS ON SILICON SUBSTRATES FOR EFFECTIVE CONFOCAL LASER MICROSCOPY - Methods of performing confocal laser microscopy on a polymer array disposed on a silicon wafer substrate, the method comprising the steps of providing a silicon wafer substrate having a top side and a bottom side, coating the top side of the silicon wafer with an oxide coating to provide an oxide coated wafer, covalently coupling a plurality of probes to the top side of the coated wafer to provide a fixed polymer array, hybridizing the fixed polymer array with a plurality of labeled ligands, and assaying for one or more hybridized ligands using confocal laser fluorescence microscopy to detect hybridization are provided. | 2011-07-28 |
20110183870 | GENE EXPRESSION PROFILES ASSOCIATED WITH LEAN PHENOTYPE AND USES THEREOF - Gene expression profiles associated with improved or maintained lean body mass or reduced body fat are disclosed. The gene expression profiles were determined in adipose, liver, and muscle tissue of animals subjected to lean-promoting regimens such as consumption of a high protein diet, ingestion of conjugated linolenic acid, and/or increased exercise. Methods of using such profiles for the identification of pharmaceutical substances, nutraceutical substances, dietary substances, or treatment regimens that modulate or contribute to desired phenotypes in animals are also disclosed | 2011-07-28 |
20110183871 | Method and composition for curing lost circulation - The invention provides a system made of fibers and a material able to exhibit reverse solubility. The invention preferably is used in a well and as a method to cure lost circulation. | 2011-07-28 |
20110183872 | METHODS FOR GAS WELL TREATMENT - Methods for using a microemulsion system are disclosed which comprises a solvent subsystem, a co-solvent subsystem and a surfactant subsystem comprises at least one monoalkyl branched propoxy sulfate anionic surfactant, where the microemulsion system are useful in drilling, producing, remediation, and fracturing application to reduce water blocks and water blocking in formation of a producing formation. | 2011-07-28 |
20110183873 | Open-Hole Wellbore Lining - Embodiments of the present invention provide compositions and methods for lining a wellbore. In certain aspects, the compositions and methods comprise providing a fluid composition that is solidifiable or gellable on exposure to actinic radiation of a predetermined wavelength at the wall of open-hole wellbore and providing actinic radiation at the predetermined wavelength to solidify or gel the composition. The predetermined wavelength lies in a range from 100 nm to 1500 nm. | 2011-07-28 |
20110183874 | LOST CIRCULATION MATERIAL FOR OILFIELD USE - A composition for reducing lost circulation in a well, while drilling the well with a drilling mud, which is composed of a base fluid, a mixture of particles, and a blend of fibers. The composition is used by stopping drilling with the mud, injecting a spacer, injecting the water-based composition, injecting a spacer, and resuming drilling with the oil-based mud. | 2011-07-28 |
20110183875 | Vulcanisable guanidine-free mixtures containing ethylene acrylate (AEM), polyacrylate (ACM) and/or hydrogenated acrylnitrile (HNBR)-based rubbers compounds, vulcanisates, prepared by cross-linking this vulcanisable mixtures and their use - The present invention relates vulcanisable guanidine-free mixtures containing ethylene acrylate (AEM), polyacrylate (ACM) and/or hydrogenated acrylonitrile (HNBR)-based rubbers compounds having an improved scorch resistance, to vulcanisates, prepared by cross-linking this vulcanisable mixtures and their use in automotive, oil-field and/or off-shore applications. | 2011-07-28 |
20110183876 | GREASE COMPOSITION AND BEARING - The invention provides a grease composition suitable for being packed in roll bearings to be lubricated at elevated temperatures and a bearing in which the above-mentioned grease composition is packed. In the grease composition containing a base oil, a urea-containing thickener and an additive, the additive includes an overbased metal sulfonate and the amount of the overbased metal sulfonate is 0.05 to 1.00 mass % with respect to the total amount of the grease composition. The bearing has the above-mentioned grease composition sealed therein. | 2011-07-28 |
20110183877 | LUBRICATING GREASE COMPOSITIONS - Lubricating grease composition comprising: (i) a base oil; and (ii) a thickener system comprising (i) a lithium soap of a first carboxylic acid selected from C | 2011-07-28 |
20110183878 | Ethylene Copolymers, Methods for Their Production, and Use - Provided is an ethylene copolymer having 40 wt. % to 70 wt. % of units derived from ethylene and at least 30 wt. % of units derived from at least one α-olefin having 3 to 20 carbon atoms and has the following properties:
| 2011-07-28 |
20110183879 | Lubricating Oil Compositions and Method for Making Them - Provided are ethylene propylene copolymers compositions thereof and methods for making the same. The composition may include an ethylene copolymer, comprising 40 wt % to 70 wt % of units derived from ethylene, and at least 30 wt % of units derived from at least one α-olefin having 3 to 20 carbon atoms. The composition can have a melting point (Tm) in ° C., as measured by DSC, that satisfies the relation: Tm>3.4×E−180, where E is the weight % of units derived from ethylene in the copolymer. The composition can also have a Mw/Mn ratio of about 1.5 to about 3.5. The composition can further have a content of Group 4 metals derived from a catalyst of 25 ppm or less. | 2011-07-28 |
20110183880 | (METH) ACRYLIC ACID-BASED COPOLYMER, METHOD FOR PRODUCING THE SAME AND DETERGENT COMPOSITION USING THE SAME - The present invention provides a (meth)acrylic acid-based copolymer useful to a detergent which is excellent in efficient removal capability of soil of clothes (in particular, hydrophobic soil such as collar dirt or greasy dirt), and prevention capability of soil redeposition, not to re-adhere the soil to laundries, even in carrying out washing with small amount of water. The present invention provides a (meth)acrylic acid-based copolymer comprising, as repeating units: a repeating unit (a) derived from a (meth)acrylic acid-based monomer (A) represented by the formula (1); and a repeating unit (b) derived from an alkyl(meth)acrylate-based monomer (B) represented by the formula (2) or a repeating unit (c) derived from a vinyl aromatic-based monomer (C); and 1 or, 2 or more kinds of repeating units (d) selected from the group consisting of a repeating unit (d-1) derived from an unsaturated monomer (D-1) represented by the formula (3), a repeating unit (d-2) derived from an unsaturated monomer (D-2) represented by the formula (4) a repeating unit (d-3) derived from a hydroxyalkyl(meth)acrylate-based monomer (D-3) represented by the formula (5), and a repeating unit (d-4) derived from a sulfonic acid group containing monomer (D-4) represented by the formula (6). Furthermore, the present invention provides a method for producing said (meth)acrylic acid-based copolymer. | 2011-07-28 |
20110183881 | Laundry Detergent Bar Composition - The present invention relates to a non-phosphate laundry detergent bar composition having specific polycarboxylate compounds as builders instead of the traditional phosphate compound builders. | 2011-07-28 |
20110183882 | Soy Ester Based Multi-Purpose Solvent - A multi-purpose solvent includes a soy ester material and includes less than 25 Grams Per Liter (GPL) of Volatile Organic Compound (VOC) rating which permits the multi-purpose solvent to be used for cleaning in government regulated areas. The desire to reduce VOCs is well recognized. The multi-purpose solvent of the present invention performs as well as known cleaning products (for example, xylene or MEK) having greater than 25 grams per liter VOC products. Further, the multi-purpose solvent according to the present invention has less than one tenth of the hazardous ingredients present in the other multi-purpose solvents. The multi-purpose solvent is suitable for reducing water and oil based coatings and material and may be used as a cleaner or thinner. | 2011-07-28 |
20110183883 | COMPOSITION - The present invention provides the use of a composition comprising a polyalkyleneimine and/or salts or derivative thereof for the prevention of corrosion of non-metallic in organic items during a washing or rinsing process, in particular during an automatic dishwashing process. | 2011-07-28 |
20110183884 | PAN-ANTIVIRAL PEPTIDES FOR PROTEIN KINASE INHIBITION - A method of inhibiting protein kinases by administering polypeptides derived from alpha-neurotoxin, and inhibiting protein kinases. Diseases treated thereby include cancer, influenza, Tourette's syndrome, pain, and neurological deficits. | 2011-07-28 |
20110183885 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 2011-07-28 |
20110183886 | MELANOCORTIN RECEPTOR LIGANDS - The present invention is directed to compounds according to formula, | 2011-07-28 |
20110183887 | METHODS AND COMPOSITIONS FOR THE REDUCTION OF NEUTROPHIL INFLUX AND THE TREATMENT OF BRONCHOPULMONARY DISPLASIA, RESPIRATORY DISTRESS SYNDROME, CHRONIC LUNG DISEASE, PULMONARY FIBROSIS, ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans. | 2011-07-28 |
20110183888 | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases - The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including Alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders. | 2011-07-28 |
20110183889 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS - This invention pertains to the surprising discovery that salicylanilides, e.g., niclosamide and/or niclosamide analogues can be reacted with a therapeutically active peptide to produce a modified peptide complex that shows increased resistance to proteolysis and that shows higher bioactivity when orally administered than the unmodified peptide. | 2011-07-28 |
20110183890 | METHODS FOR MODULATING ANGIOGENESIS VIA DYSTROPHIN DP71 - The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject. | 2011-07-28 |
20110183891 | Methods and Compositions for Inhibiting Fungal Infection and Disease - The present invention describes a previously unknown interaction between secreted aspartic proteases (SAPs), including SAPs 4-6 of | 2011-07-28 |
20110183892 | METHODS FOR THE TREATMENT OF VIRAL CONDITIONS - The invention is directed to a method of stimulating PRF in a viral cell by administering an aminoglycoside antibiotic to said cell. In another embodiment, the invention is directed to a method of inhibiting viral replication by administering an aminoglycoside antibiotic to a viral cell. The invention is also directed to method of treating a viral infection in a patient suffering therefrom comprising administering to said patient an aminoglycoside antibiotic. | 2011-07-28 |
20110183893 | NON-NATURAL MIC PROTEINS - This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein. | 2011-07-28 |
20110183894 | ANTIVIRAL ACTIVITY OF THE PROTEIN SCYTOVIRIN AND METHODS OF USE - The present invention features methods of treating or preventing a viral infection in a subject, methods of inhibiting a virus in a biological sample, and methods of treating or preventing a viral infection caused by a virus in or on the skin or mucus membrane. The instant invention describes novel methods for treating viral infections, in particular infections caused by high mannose enveloped viruses, for example hepatitis C virus (HCV). | 2011-07-28 |
20110183895 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS - The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): | 2011-07-28 |
20110183896 | ENHANCEMENT OF BACILLUS THURINGIENSIS CRY PROTEIN TOXICITIES TO COLEOPTERANS, AND NOVEL INSECT CADHERIN FRAGMENTS - The subject invention relates in part to the discovery that a fragment from a cadherin of the western corn rootworm enhances Cry3 toxicity to larvae of naturally susceptible species. The subject invention also relates in part to the discovery that a cadherin fragment from a beetle enhances Cry3Aa and Cry3Bb toxicity to coleopteran larvae, particularly those in the family Chrysomelidae. Such cadherin fragments are referred to as Bt Boosters (BtBs). The subject invention can be extended to the use of BtBs with other coleopteran-toxic Cry proteins for controlling a wide range of coleopterans. | 2011-07-28 |
20110183897 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 2011-07-28 |
20110183898 | COMPOSITIONS FOR DELIVERING PEPTIDE YY AND PYY AG0NISTS - The present invention provides a composition (e.g., a pharmaceutical composition) comprising at least one delivery agent compound and at least one of peptide YY (PYY) and a PYY agonist. Preferably, the composition includes a therapeutically effective amount of peptide YY or the PYY agonist and the delivery agent compound. The composition of the present invention facilitates the delivery of PYY, a PYY agonist, or a mixture thereof and increases its bioavailability compared to administration without the delivery agent compound. PPY and PYY agonists possess activity as agents to reduce nutrient availability, including reduction of food intake. | 2011-07-28 |
20110183899 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY - The invention relates to methods and compositions for the treatment of obesity. The methods and compositions relate to the use of an agent that reduces or prevents endoplasmic reticulum stress in conjunction with leptin. | 2011-07-28 |
20110183900 | High Caloric Enteral Formulations - Compositions and methods relating to high caloric enteral formulations are disclosed herein. The invention provides a dietary composition comprising hydrolyzed soy protein and having a low viscosity and acceptable shelf life. Methods of using the dietary compositions of the invention are also disclosed. | 2011-07-28 |
20110183901 | Superior Control of Blood Glucose in Diabetes Treatment - Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin. | 2011-07-28 |
20110183902 | PHARMACEUTICAL COMPOSITION COMPRISING OXYNTOMODULIN DERIVATIVES AND A METHOD FOR REDUCING BODY WEIGHT USING THE COMPOSITION - Modified oxyntomodulin derivatives. Such derivatives can be used for the treatment of metabolic diseases such as diabetes and obesity. | 2011-07-28 |
20110183903 | USE OF PEGylated IGF-I VARIANTS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS - The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where the PEG is attached to at least one lysine residue. The invention also relates to methods for the treatment, prevention and/or delay of progression of neuromuscular disorders, in particular amyotrophic lateral sclerosis (ALS) by administering a therapeutically effective amount of the pharmaceutical composition of the invention. | 2011-07-28 |
20110183904 | METHODS AND COMPOSITIONS FOR ALTERING BEHAVIOR ASSOCIATED WITH AUTISM SPECTRUM DISORDER - The present invention discloses methods for the diagnosis and treatment of autism. The diagnostic tools provided use analysis of levels of G-protein expression, oxytocin, and vasopressin. Treatment for autism spectrum disorder and symptoms of autism spectrum disorder, especially repetitive behavior, is also provided. | 2011-07-28 |
20110183905 | PHARMACEUTICAL COMPOSITIONS - A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent. | 2011-07-28 |
20110183906 | FACTOR IX CONJUGATES WITH EXTENDED HALF-LIVES - The present invention relates to conjugates of Factor IX that have been modified to include a biocompatible polymer moiety. The Factor IX conjugates are substantially free of contamination by Factor IXa. The Factor IX conjugates have improved pharmacokinetic properties, such as increased half-life, which results in dose sparing and less frequent administration. | 2011-07-28 |
20110183907 | FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences. | 2011-07-28 |
20110183908 | YOPM AS DELIVERY VEHICLE FOR CARGO MOLECULES AND AS BIOLOGICAL THERAPEUTIC FOR IMMUNOMODULATION OF INFLAMMATORY REACTIONS - The present invention relates to the use of | 2011-07-28 |
20110183909 | Treatment of Mood and Anxiety Disorders - The invention relates to a selective inhibitor of Elk-1 or MSK-1 activation for use in the prevention and/or treatment of mood and anxiety disorders. | 2011-07-28 |
20110183910 | BIGLYCAN AND RELATED THERAPEUTICS AND METHODS OF USE - The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. | 2011-07-28 |
20110183911 | METHOD FOR IMPROVING NEUROTRANSMISSION FAILURE USING A NOVEL AGENT - A novel medicament for ameliorating neurotransmission dysfunction diseases is provided. A medicament for ameliorating neurotransmission dysfunction diseases comprising as a main active ingredient preferably a selenocysteine-containing protein such as Selenoprotein P or a selenocysteine-containing peptide that consists of said protein or a series of said peptides. A medicament suited for ameliorating neurotransmission dysfunction diseases caused by various pathological conditions is provided. | 2011-07-28 |
20110183912 | AGENT FOR PROMOTING NEURONAL DIFFERENTIATION AND METHOD THEREFOR - An agent for promoting neuronal differentiation of a neural stem/progenitor cell includes an inhibitor of function of a COUP-TFI protein and/or a COUP-TFII protein. To promote neuronal differentiation of a neural stem/progenitor cell, the agent is administered to the neural stem/progenitor cell to inhibit function of a COUP-TFI protein and/or a COUP-TFII protein. | 2011-07-28 |
20110183913 | NOVEL LIPID DIPEPTIDE AND GEL - There is provided a gelator that is capable of forming a gel by an extremely small amount of addition in a wide pH range from acidic to alkaline regions, and a gel having high environmental compatibility, biocompatibility, and biodegradability. A gelator comprising: a lipid peptide of Formula (1) wherein R | 2011-07-28 |
20110183914 | Personal Care Compositions - Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen. | 2011-07-28 |
20110183915 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells - A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition. | 2011-07-28 |
20110183916 | Apo-2 Ligand - A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided. | 2011-07-28 |
20110183917 | P53 Activator Peptides - The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof. | 2011-07-28 |
20110183918 | Method of Treating Leukemia Using Rcie Prolamin - The present invention relates to a method of treating leukemia using rice prolamin, and a pharmaceutical composition for treating leukemia, comprising an effective amount of rice prolamin together with one or more pharmaceutically acceptable carriers or excipients. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (PBMC) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia U937 cells. The rice prolamin is gluten-free, thus will not trigger gastrointestinal allergic reaction. | 2011-07-28 |
20110183919 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. | 2011-07-28 |
20110183920 | MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS - This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life. | 2011-07-28 |
20110183921 | PEPTIDES CAPABLE OF MODULATING THE FUNCTION OF TIRC7 - Provided are peptides capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs) derived from the third extracellular domain of T-cell immune response cDNA7 (TIRC7) costimulatory molecule are described. Compositions comprising such peptides and their use for the treatment of immune diseases are provided. | 2011-07-28 |
20110183922 | PEPTIDES THAT ENHANCE ACETYLCHOLINESTERASE EXPRESSION - The present invention provides novel chimeric peptides and novel methods for treating animals including humans by administering the novel chimeric peptides. In particular, the invention is useful for enhancing endogenous acetylcholinesterase expression in individuals exposed to organophosphate compounds, such as nerve gases and pesticides. | 2011-07-28 |
20110183923 | PEPTIDE ANTAGONISTS OF ZONULIN AND METHODS FOR USE OF THE SAME - Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions. | 2011-07-28 |
20110183924 | Methods and systems for annotating biomolecular sequences - A method of annotating biomolecular sequences. The method comprises (a) computationally clustering the biomolecular sequences according to a progressive homology range, to thereby generate a plurality of clusters each being of a predetermined homology of the homology range; and (b) assigning at least one ontology to each cluster of the plurality of clusters, the at least one ontology being: (i) derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or (ii) generated from analysis of the at least one biomolecular sequence of each cluster thereby annotating biomolecular sequences. | 2011-07-28 |
20110183925 | ANTI-INFLAMMATORY PEPTIDE - Provided is an anti-inflammatory composition which has a high efficacy, causes no concern about side effects, is easy to ingest, and can also be administered for a long period of time because of its low cost and high safety. The present invention relates to a peptide comprising an amino acid sequence represented by pyroGlu-(X)n-A or a salt thereof, wherein X is independently Gln, Asn, or Pro; A represents Gln, Asn, Leu, Ile, Met, Val, or Phe; and n represents an integer of 0 to 2, and an anti-inflammatory composition comprising the same. | 2011-07-28 |
20110183926 | TREATMENT USING CONTINUOUS LOW DOSE APPLICATION OF SUGAR ANALOGS - Methods and uses of low dosage nonmetabolizable D-glucose analogs and mannose analogs such as 2-deoxy-D-glucose, 5-thio-D-glucose, 2-fluoro-2-deoxy-D-glucose, 2-chloro-2-deoxy-D-glucose, 2-bromo-2-deoxy-D-glueose, 2-deoxy-2-fluoro-mannose, 2-deoxy-2-chloro-mannose, 3-deoxy mannose, 4-deoxy mannose, and 2,3 didioxy mannose, for the treatment of tumors. | 2011-07-28 |
20110183927 | Compositions Comprising Sugar-Cysteine Products - The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same. | 2011-07-28 |
20110183928 | 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof - The present application relates to novel 3-cyanoalkyl- and 3-hydroxyalkyl-substituted indole derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of cardiovascular diseases. | 2011-07-28 |
20110183929 | STANDARDIZED EXTRACT AND FRACTION FROM HANCORNIA SPECIOSA LEAVES AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention describes a standardized extract obtained from the leaves of | 2011-07-28 |
20110183930 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES - The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application. | 2011-07-28 |
20110183931 | POTENT LNA OLIGONUCLEOTIDES FOR THE INHIBITION OF HIF-1A EXPRESSION - The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-( | 2011-07-28 |
20110183932 | THREE-COMPONENT BONE CEMENT - A paste is provided from which bone cement can be formed, which is to the largest extent possible bubble-free and has a high impact strength. The paste includes (i) 15-50 weight percent of at least one mono-functional, hydrophobic methacrylic acid ester, (ii) 40-85 weight percent of at least one filler, (iii) 0.01-4 weight percent of at least one radical initiator soluble in the methacrylic acid ester (i) and having at least one peroxide group, (iv) 0.01-4 weight percent of at least one radical initiator soluble in the methacrylic acid ester (i) and having no peroxide groups, (v) 0.000001-3 weight percent of at least one accelerator soluble in the methacrylic acid ester (i) and capable of forming radicals from the radical initiators according to (iii) and (iv), (vi) 0.001-5 weight percent of at least one halide salt, and (vii) 0.2-3 weight percent of at least one cross-linking agent. | 2011-07-28 |
20110183933 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS - In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits. | 2011-07-28 |
20110183934 | METHODS AND COMPOSITIONS TO IMPROVE GERM CELL AND EMBRYO SURVIVAL AND FUNCTION - Sperm, oocyte, and embryo survival and function is improved in vivo or in vitro by the use of a polysaccharide containing arabinose, galactose and/or hexuronic acid. In particular, a nonspermicidal lubricant containing such a polysaccharide (e.g., gum arabic, pectin, or galacturonic acid) increases the fertilization potential of the sperm during coitus, artificial insemination or sperm collection. Similarly, a freezing medium containing a polysaccharide containing arabinose, galactose and/or hexuronic acid enhances sperm, oocyte, or embryo viability. | 2011-07-28 |
20110183935 | HEARTWATER - There is provided a water product for general consumer comprising water suitable for human consumption and a food additive in the amount effective to alter a level of serum marker that indicates a likelihood of cardiovascular disease, thereby the water product is intended to lower the risk of cardiovascular disease of said general consumer. The preferred additive is Barliv™ betafiber. | 2011-07-28 |
20110183936 | REGIMENS FOR INTRA-ARTICULAR VISCOSUPPLEMENTATION - The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5% (w/w) of which is in a gel form, such as, e.g., hylan B. In an illustrative embodiment, hylan G-F 20 (Synvisc®) is administered in a single intra-articular knee injection of 6±2 ml. | 2011-07-28 |
20110183937 | Agent for Combating Ectoparasites - Disclosed is a composition for killing ectoparasites and/or their eggs, comprising at least one volatile, at room temperature liquid, non-polar organic solvent, 1 to 10 wt.-%, based on the total composition, of at least one spreading agent; and 35 to 65 wt.-%, based on the total composition, of at least one polysiloxane having a viscosity of greater than 90 cSt. | 2011-07-28 |
20110183938 | 1,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2011-07-28 |
20110183939 | NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides a novel P2X | 2011-07-28 |
20110183940 | CHEMICAL COMPOUNDS - The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 2011-07-28 |
20110183941 | Herbicide consisting of a glyphosate formulation containing a surfactant consisting in a branched alkyl alcohol polyethoxylated or polypropoxylated and a mixture of alkylamines - Linear alkyl amine polyethoxylated containing in the alkyl chain 16 to 20 carbon atoms are worldwide used as surfactants for herbicides based on glyphosate. | 2011-07-28 |
20110183942 | Methods and Compositions for Treating Alzheimer's Disease - A method is disclosed for inhibiting the build-up of amyloid plaques in the brain of a patient with at least one risk factor for, or a diagnosis of, Alzheimer's Disease by administering to the patient an amount of one or more compounds effective to inhibit the phosphorylative activity of eEF2K, thereby inhibiting amyloid plaque deposition. | 2011-07-28 |
20110183943 | CONCURRENT THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE RELATED DISEASES - A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy. | 2011-07-28 |
20110183944 | SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS - Compositions for controlled release of one or more therapeutic agents where the composition is essentially free of excipients are disclosed. In particular, compositions comprising a HMG-CoA reductase inhibitor, particularly simvastatin, and a NSAID, such as a COX-2 inhibitor, particularly celecoxib, in which greater than 90% of the weight of the composition is made up of the HMG-CoA reductase inhibitor and NSAID are provided. | 2011-07-28 |
20110183945 | LONG ACTING CURCUMIN DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF - The invention provides a long acting curcumin derivative, preparation method and pharmaceutical use thereof, wherein said long acting curcumin derivative having the general structural formula disclosed herein, wherein R1 and R2 are hydrogen or methoxyl; R3 and R4 are each independently selected from C1-C50 alkyl. Compared with cuminoids, the inventive long acting curcumin derivative has a better release effect, a higher bioavailability and pharmaceutical activity, and thus can be useful for the treatment of diseases such as depression and cancer. | 2011-07-28 |
20110183946 | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Methods of Providing Neuroprotection or Treating or Inhibiting Progression of Glaucoma - A complex comprises at least an α | 2011-07-28 |
20110183947 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS - The invention provides a series of -αketoheterocyclic compounds, for example, compounds of formula (I). The compounds can inhibit fatty acid amide hydrolase and can be useful for treatment of malconditions modulated by fatty acid amide hydrolase. The invention further provides methods of making compounds of formula (I), useful intermediates for the preparation of compounds of formula (I), and methods of using compounds of formula (I) and compositions thereof. | 2011-07-28 |
20110183948 | TREATMENT OF FIBROTIC CONDITIONS USING HEDGEHOG INHIBITORS - Provided is a method of treating a fibrotic condition with a hedgehog inhibitor. | 2011-07-28 |
20110183949 | Use of Fulvestrant in the Treatment of Resistant Breast Cancer - The invention relates to the use of fulvestrant in the treatment of breast cancer in patients who have previously been treated with a Selective Estrogen Receptor Modulator (SERM) and an aromatase inhibitor. | 2011-07-28 |
20110183950 | TREATMENT OF VAGINAL ATROPHY IN WOMEN WITH TUMOR PATHOLOGY RISK - The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women, said women having a high probability of developing an estrogen-dependent tumor or suffering or having suffered from an estrogen-dependent tumor. | 2011-07-28 |